A consensus statement on the use of ketamine in the treatment of mood disorders

JAMA Psychiatry

Volumn 74, Issue 4, 2017, Pages 399-405

  Sanacora, Gerard ^a   Frye, Mark A ^b   McDonald, William ^c   Mathew, Sanjay J ^d,e   Turner, Mason S ^f   Schatzberg, Alan F ^g   Summergrad, Paul ^h   Nemeroff, Charles B ⁱ  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f KAISER PERMANENTE   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE;

ANTIDEPRESSANT ACTIVITY; CONSENSUS; DRUG EFFICACY; FOLLOW UP; HUMAN; MOOD DISORDER; PATIENT SELECTION; PERSONAL EXPERIENCE; PRACTICE GUIDELINE; REVIEW; SAMPLE SIZE; TRAINING; TREATMENT OUTCOME; ANXIETY DISORDERS; CONSENSUS DEVELOPMENT; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOSE RESPONSE; EVIDENCE BASED MEDICINE; INTRAVENOUS DRUG ADMINISTRATION; MOOD DISORDERS; OFF LABEL DRUG USE; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT;

ANXIETY DISORDERS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOSE-RESPONSE RELATIONSHIP, DRUG; EVIDENCE-BASED MEDICINE; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MOOD DISORDERS; OFF-LABEL USE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 85017591670     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2017.0080     Document Type: Review

References (41)

1. Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB; APA Council of Research Task Forceon Novel Biomarkers and Treatments. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry. 2015; 172(10):950-966.
2. Sisti D, Segal AG, Thase ME. Proceed with caution: off-label ketamine treatment for major depressive disorder. Curr Psychiatry Rep. 2014;16 (12):527.
3. Zhang MW, Harris KM, Ho RC. Is off-label repeat prescription of ketamine as a rapid antidepressant safe? controversies, ethical concerns, and legal implications. BMC Med Ethics. 2016;17(1):4.
4. Xu Y, Hackett M, Carter G, et al. Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2016;19(4):pyv124. doi:10.1093/ijnp/pyv124
5. Coyle CM, Laws KR. The use of ketamine asan antidepressant: a systematic review and meta-analysis. Hum Psychopharmacol. 2015;30(3): 152-163.
6. Lee EE, Della Selva MP, Liu A, Himelhoch S. Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis. Gen Hosp Psychiatry. 2015;37(2):178-184.
7. McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. Asystematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med. 2015;45(4):693-704.
8. Fond G, Loundou A, Rabu C, et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl). 2014;231(18):3663-3676.
9. Wan LB, Levitch CF, Perez AM, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015;76(3):247-252.
10. McCloud TL, Caddy C, Jochim J, et al. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database Syst Rev. 2015;9(9):CD011611.
11. Caddy C, Amit BH, McCloud TL, et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev. 2015;9(9):CD011612.
12. Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74(4):250-256.
13. Singh JB, Fedgchin M, Daly EJ, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173(8):816-826.
14. Kristensen SD, Knuuti J, Saraste A, et al; Authors/Task Force Members. 2014 ESC/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management: the Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol. 2014;31 (10):517-573.
15. Eagle KA, Berger PB, Calkins H, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation. 2002;105(10): 1257-1267
16. Fleisher LA, Fleischmann KE, Auerbach AD, et al; American College of Cardiology; American Heart Association. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014;64 (22):e77-e137
17. Apfelbaum JL, Connis RT, Nickinovich DG, et al; Committee on Standards and Practice Parameters; American Society of Anesthesiologists Task Force on Preanesthesia Evaluation. Practice advisory for preanesthesia evaluation: an updated report by the American Society of Anesthesiologists Task Force on Preanesthesia Evaluation. Anesthesiology. 2012; 116(3):522-538.
18. Miller RD. Miller's Anesthesia. 7th ed. Philadelphia, PA: Churchill Livingstone; 2010.
19. Grant IS, Nimmo WS, McNicol LR, Clements JA. Ketamine disposition in children and adults. Br J Anaesth. 1983;55(11):1107-1111.
20. Bowdle TA, Horita A, Kharasch ED. The Pharmacological Basis of Anesthesiology. New York, NY: Churchill Livingstone; 1994
21. Perry EB Jr, Cramer JA, Cho HS, et al; Yale Ketamine Study Group. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology (Berl). 2007;192(2):253-260.
22. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51(3):199-214
23. American Society of Anesthesiologists. Statement on granting privileges for administration of moderate sedation to practitioners who are not anesthesia professionals (approved by the ASA House of Delegates on October 25, 2005, and reaffirmed on October 26, 2016). http://www.asahq.org/~/media/Sites/ASAHQ/Files/Public/Resources/standards-guidelines/statement-on-granting-privileges-to-nonanesthesiologist-administering-physicians-deep-sedation.pdf. Accessed December 19, 2016.
24. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-354
25. Singh JB, Fedgchin M, Daly E, et al. Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry. 2016;80 (6):424-431.
26. Rasmussen KG, Lineberry TW, Galardy CW, et al. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol. 2013;27(5): 444-450.
27. Vande Voort JL, Morgan RJ, Kung S, et al. Continuation phase intravenous ketamine in adults with treatment-resistant depression. J Affect Disord. 2016;206:300-304
28. Cusin C, Ionescu DF, Pavone KJ, et al. Ketamine augmentation for outpatients with treatment-resistant depression: preliminary evidence for two-step intravenous dose escalation. Aust NZ J Psychiatry. 2017;51(1):55-64
29. Lenze EJ, Farber NB, Kharasch E, et al. Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: a pilot randomised controlled trial. World J Biol Psychiatry. 2016;17(3):230-238.
30. Drake LM, Chen SC, Rex DK. Efficacy of bispectral monitoring as an adjunct to nurse-administered propofol sedation for colonoscopy: a randomized controlled trial. ∗4m J Gastroenterol. 2006;101(9):2003-2007
31. Shiroma PR, Johns B, Kuskowski M, et al. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord. 2014;155:123-129.
32. Diamond PR, Farmery AD, Atkinson S, et al. Ketamine infusionsfortreatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol. 2014;28(6):536-544.
33. Ghasemi M, Kazemi MH, Yoosefi A, et al. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Res. 2014;215(2):355-361.
34. Segmiller F, Rüther T, Linhardt A, et al. Repeated S-ketamine infusions in therapy resistant depression: a case series. J Clin Pharmacol. 2013; 53(9):996-998.
35. Blier P, Zigman D, Blier J. On the safety and benefits of repeated intravenous injections of ketamine for depression. Biol Psychiatry. 2012;72 (4):e11-e12.
36. Szymkowicz SM, Finnegan N, Dale RM. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression. J Affect Disord. 2013;147(1-3):416-420.
37. Morgan CJ, Riccelli M, Maitland CH, Curran HV. Long-term effects of ketamine: evidence for a persisting impairmentofsource memory in recreational users. Drug Alcohol Depend. 2004;75 (3):301-308.
38. Wood D. Ketamine and damage to the urinary tract. Addiction. 2013;108(8):1515-1516.
39. Morgan CJ, Curran HV; Independent Scientific Committee onDrugs. Ketamine use:areview. Addiction. 2012;107(1):27-38.
40. Kalsi SS, Wood DM, Dargan PI. The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerg Health Threats J. 2011;4:7107.
41. Schak KM, Vande Voort JL, Johnson EK, et al. Potential risks of poorly monitored ketamine use in depression treatment. Am J Psychiatry. 2016;173 (3):215-218.